Caisson Biotech Information

Caisson Biotech is a privately held biopharmaceutical company focused on the commercialization of heparosan for drug delivery. Heparosan is a polymer composed of sugars. It naturally exists in the human body and is broken down by the body’s natural processes. Caisson’s HEPtune® technology offers a paradigm shift in patient care and better compliance in multiple therapeutic areas to improve the quality of life for millions of patients. Caisson’s platform benefits patients with its non-toxicity potential, its stability in the bloodstream, and on the shelf, and its ability to increase resonance time of a drug, requiring less frequent administration. These attributes lead to increased compliance and safety, and thus is a transformative advancement for those with life-long diseases. Caisson’s approach is a superior alternative to the gold standard industrial polymer polyethylene glycol and other drug delivery technologies, and allows for synthesis of sugar polymers with a very narrow size distribution as well as defined chemical activation that facilitates selective coupling to therapeutics or other drug vehicles. Caisson Biotech is a portfolio company of Emergent Technologies Inc (www.etibio.com), an Austin, TX life-sciences based management firm focused on unlocking the commercial potential of scientific breakthroughs.